Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 24Nivolumab 13atezolizumab 7Ipilimumab 6Cyclophosphamide 6fludarabine 5Specimen Handling 5Magnetic Resonance Spectroscopy 5aldesleukin 4Interleukin-2 4Biopsy 4durvalumab 3cemiplimab 3Docetaxel 3tislelizumab 2osimertinib 2fludarabine phosphate 2enzalutamide 2avelumab 2X-Rays 2Ritonavir 2Radiotherapy 2Observation 2Methods 2Immunoglobulin G 2IFL protocol 2Drug Therapy 2zimberelimab 1utomilumab 1ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × cyclopropapyrroloindole × Dermatologic × Clear all
NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 2/3 Recruiting
200 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡